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Membrane particles generated 
from mesenchymal stromal cells 
modulate immune responses 
by selective targeting of pro-
inflammatory monocytes
Fabiany da C. Gonçalves  1,2, Franka Luk3, Sander S. Korevaar3, Rachid Bouzid3, Ana H. 
Paz1,2, Carmen López-Iglesias4, Carla C. Baan3, Ana Merino3 & Martin J. Hoogduijn3
Mesenchymal stromal cells (MSC) are a promising therapy for immunological disorders. However, 
culture expanded MSC are large and get trapped in the capillary networks of the lungs after intravenous 
infusion, where they have a short survival time. Hypothetically, living cells are a risk for tumor 
formation. To reduce risks associated with MSC infusion and improve the distribution in the body, we 
generated membrane particles (MP) of MSC and MSC stimulated with IFN-γ (MPγ). Tracking analysis 
and electron microscopy indicated that the average size of MP was 120 nm, and they showed a round 
shape. MP exhibited ATPase, nucleotidase and esterase activity, indicating they are enzymatically 
active. MP and MPγ did not physically interact with T cells and had no effect on CD4+ and CD8+ T cells 
proliferation. However, MP and MPγ selectively bound to monocytes and decreased the frequency of 
pro-inflammatory CD14+CD16+ monocytes by induction of selective apoptosis. MP and MPγ increased 
the percentage of CD90 positive monocytes, and MPγ but not MP increased the percentage of anti-
inflammatory PD-L1 monocytes. MPγ increased mRNA expression of PD-L1 in monocytes. These 
data demonstrate that MP have immunomodulatory properties and have potential as a novel cell-free 
therapy for treatment of immunological disorders.
Mesenchymal stromal cells (MSC) are studied as an experimental therapy for immunological disorders due to 
their diverse immunomodulatory properties1–3. Multiple clinical trials with MSC in inflammatory disease and 
transplantation have been conducted, such as in graft versus host disease4, kidney transplantation5, and Crohn’s 
disease6. The outcomes of several of these trials hint towards a beneficial immunomodulatory effect of MSC, but 
they are not conclusive7. This is partly due to the small patient numbers, to the lack of understanding of the effects 
of MSC after administration, and perhaps because MSC derived from different tissue sources are used which dis-
play distinct paracrine potential and immune regulatory properties. Several authors have compared the capacity 
of MSC from various tissue sources to suppress peripheral blood B, T and NK cells, and it has been reported that 
adipose tissue-derived MSC (AT-MSC) have a stronger immunomodulatory effect than MSC from other tissue 
sources8,9. The function of MSC as immunomodulatory agent has been attributed to a variety of mechanisms, 
notably cytokine and chemokine secretion10,11. Multiple pathways have been identified to play a role in in vitro 
assays, but it is unknown whether they play a role in the immunomodulatory effects of MSC administered to ani-
mals or patients. Intravenous infusion has been used as the route of MSC delivery for most preclinical studies12,13 
and clinical trials7. It was the assumption that intravenous infusion of MSC would lead to a broad bio-distribution 
of MSC. However, tracking studies have shown that the majority of MSC localize to the lungs after intravenous 
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infusion. The detainment of MSC in the lungs is due to their size (>20 μm in diameter)14,15, which exceeds the 
width of the micro-capillaries of the lungs. It has furthermore become clear that MSC have a short-term survival 
after infusion16,17. Over 90% of infused MSC are lost within 24 h after infusion. Even though infused MSC end 
up in the lungs and disappear rapidly, they exert immunomodulatory effects. The short lifespan of MSC after 
intravenous infusion questions the contribution of secreted anti-inflammatory factors by MSC to the modulation 
of immune responses.
Recent work demonstrated that heat inactivated MSC that lost their capacity to secrete factors maintain 
their immunomodulatory capacity after intravenous infusion in an LPS-induced sepsis model, suggesting that 
cell membrane dependent interactions with immune cells are responsible for the immune regulatory effects18. 
MSC express immunomodulatory molecules on their membrane such as Toll-like receptors (TLRs)19, ATPases20 
and CD73 (ecto-5′-nucleotidase, Ecto5′NTase) which dephosphorylate ATP into AMP and AMP into adeno-
sine, respectively21. This is an important immunomodulatory function as adenosine has immunosuppressive 
properties22. MSC also express receptors involved in differentiation pathways such as CD90 (Thy-1 membrane 
glycoprotein) that is known for its participation on the differentiation of MSC by acting as an obstacle in the 
pathway of differentiation commitment23. The ability of MSC to modulate the immune system can be enhanced 
by treatment of MSC with pro-inflammatory cytokines, in particular interferon-γ (IFN-γ) and tumor necrosis 
factor (TNF)-α24–26. Under inflammatory conditions MSC upregulate the expression of cell surface proteins with 
immune regulatory function, such as programmed death ligand 1 (PD-L1), and Fas ligand via which they directly 
target immune cells and inhibit their activation and function27.
Despite of the great potential, several factors including the practical difficulties that come with the use of 
living cells, their short survival after intravenous infusion and their poor biodistribution, have been major tech-
nical challenges to be overcome before MSC based therapy can be used for clinical application in a consistently 
therapeutic manner28. A modification in the treatment that avoids these complications but preserves the diverse 
immunoregulatory properties of MSC would therefore improve the applicability of this therapy. We propose a 
new cell-free therapy based on the generation of small plasma membrane particles (MP) from AT-MSC cultured 
under different conditions. Therefore, the aim of this study was to generate and characterize MP derived from 
MSC cultured with and without IFN-γ, analyze their immunomodulatory properties, and their interaction with 
the immune system.
Results
Characterization of adipose tissue derived mesenchymal stromal cells. Commonly used AT-MSC 
surface markers were analyzed in unstimulated and IFN-γ stimulated AT-MSC by flow cytometry (Fig. 1a). Both 
types of cells were negative for the markers CD45 and CD31, and positive for CD13, CD73, CD90 and CD105. 
There was no statistical significant difference in the percentage of unstimulated and IFN-γ stimulated AT-MSC 
expressing these markers. However, stimulation with IFN-γ significantly increased the percentage of cells positive 
for immune-markers such as HLA-I, HLA-II, and PD-L1 (Fig. 1b). The mean fluorescence intensity of the various 
markers was determined and a significant increase in the expression of CD105, HLA-II, and PD-L1 was observed 
after IFN-γ treatment (Fig. 1c).
Generation and characterization of Membrane Particles (MP). MP were generated from unstimu-
lated and IFN-γ stimulated AT-MSC. The number of cells used for each analysis was between 1 × 106–1.5 × 106 
cells (80% confluency). The size distribution of the obtained MP was studied using Nanoparticle tracking anal-
ysis (NTA). The size of the particles ranged from 63 to 700 nm (Fig. 2a), and the mode size of the samples was 
121.7 ± 35.5 nm for MP and 138.3 ± 62.1 nm for MPγ (Fig. 2b). The percentage of particles with a size larger than 
200 nm was lower than 5% in every sample.
Based on the particle concentration per ml, the average number of particles generated from each MSC was 
1.2 × 105 ± 2.7 × 104 for MP and 1.1 × 105 ± 2.8 × 104 for MPγ (Fig. 2c). There was no significant difference in size 
distribution or concentration (MP/MSC) between MP and MPγ.
The transmission electron microscopy images illustrate that MP consist of a population of particles hetero-
geneous in size with most of the particles showing a size of less than 200 nm (Fig. 2d) but some showing larger 
sizes. This result confirms the NTA analysis. It can be clearly observed that both the larger and smaller MP have 
a round shape.
Membrane Particles from AT-MSC possess enzyme activity. To analyze whether MP have enzyme 
activity, we examined the ability of MP and MPγ to convert ATP to ADP by ATPase activity, and AMP to adeno-
sine by the nucleotidase activity of CD73. The last product of these two reactions is free phosphate, so the samples 
for these assays were prepared in milliQ water to avoid contamination with free phosphates from saline buffers. 
Before measurement of enzyme activities, MP (diluted in milliQ water) were analyzed by NTA for determination 
of their concentration.
Figure 3a shows the ATPase activity (units/l) calculated from the standard curve generated with known free 
phosphate concentrations. MP and MPγ were able to convert ATP to free phosphate and the level of free phos-
phate was dependent on the concentration of MP. There was no statistical difference between MP and MPγ.
To examine whether MP and MPγ possess CD73 activity, the production of free phosphates by 2, and 1 ng 
of purified CD73 was compared with different concentrations of MP, and MPγ. Both types of MP were able to 
produce free phosphates after adding the substrate (AMP). The detection of free phosphate was dependent on 
concentration of MP and the amount of CD73 present in MP was calculated through the CD73 controls (Fig. 3b).
Esterase activity was measured by the conversion of non-fluorescent CFDA-SE to fluorescent CFSE by MP 
using flow cytometry based on a FITC fluorescence triggering strategy (Fig. 3c). This fluorescent-based flow 
cytometry protocol allows detection of particles based on positive fluorescence signals, not on size, as the average 
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MP size of 120 nm is too small to be detected by most flow cytometers. Controls used for this flow cytometry pro-
tocol were PBS + CFDA-SE, and non-labeled MP (top 2 graphs). As expected, these controls were negative as no 
CFSE fluorescence can be expected. When MP were incubated with CFDA-SE, they converted CFDA to fluores-
cent CFSE, as demonstrated by the detection of fluorescent events (lower 4 graphs) showing that MP have esterase 
activity. As an additional control, MP were diluted before CFSE staining. The results shown indicate the recording 
of all samples during 1 min. The number of detected particles decreased for more diluted samples, but the MFI of 
the CFSE staining of the particles remained the same. This means that single MP can be detected with the used 
flow cytometry strategy. Fluorescent-based flow cytometry protocols were recently described in literature29,30.
Effects of Membrane Particles on T cell proliferation. CFSE loaded human peripheral blood mononu-
clear cells (PBMC) stimulated with anti-CD3/antiCD28 antibodies were cultured with different ratios of MP for 
4 days (1:5,000, 1:10,000, 1:40,000, 1:80,000). To analyze lymphocyte proliferation, CFSE dilution was measured 
in CD4+ and CD8+ T cells. Addition of increasing concentrations of MP or MPγ did not affect the proliferation 
of CD4+ and CD8+ T cells (Fig. 4a and b).
Membrane Particles decrease the proportion of CD16+ monocytes and increase CD90+ and 
PD-L1+ monocyte subsets. Monocytes were cultured with different ratios of MP for 24 h (1:10,000, 
1:40,000, 1:80,000) to determine whether MP could affect monocyte cell surface markers expression and immune 
function. Monocytes were cultured in polypropylene tubes to avoid the adherence of the cells and differentiation 
into macrophages. Culture of monocytes in the presence of MP or MPγ treatment decreased the frequency of 
pro-inflammatory CD14+CD16+ cells at ratios of 1:40,000 (by 45% and 49%, respectively) and 1:80,000 (by 48% 
and 35%, respectively) (Fig. 5a).
Monocytes treated with MP at ratios of 1:40,000 and 1:80,000 furthermore increased the expression of 
CD90 by 17% and 25%, respectively. Meanwhile, the MPγ group showed an increase in CD90 expression at 
ratios of 1:10,000 by 8%, 1:40,000 by 16% and 1:80,000 by 20% (Fig. 5b). Moreover, MPγ treatment induced 
anti-inflammatory PD-L1 expression in monocytic cells by 16% at a 1:10,000 ratio, 43% at a 1:40,000 ratio and 
Figure 1. Immunophenotype of unstimulated and IFN-γ stimulated AT-MSC. (a) Representative flow 
cytometry analysis of the commonly used markers for MSC (CD45 and CD31, both negative, and CD105, 
CD13, CD73, CD90), and the immune-markers HLA-I, HLA-II, and PD-L1. Isotype (white histograms), 
unstimulated AT-MSC (grey histograms) and IFN-γ AT-MSC (black histograms). (b) Percentage positive cells 
and (c) Mean fluorescence intensities (MFI) of the markers on unstimulated and IFN-γ stimulated AT-MSC. 
Data are presented as mean ± SD from 5 independent experiments. P values refer to the condition without IFN-
γ. Unpaired t-test was used for statistical analysis.
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62% at a 1:80,000 ratio. MP had a smaller effect on PD-L1 expression with a 15% increase at a ratio of 1:40,000 
(Fig. 5c).
Membrane Particles affect the expression of pro- and anti-inflammatory genes in mono-
cytes. In order to examine the effect of MP on monocyte immune function, and to examine whether the 
immunophenotypic changes observed were a result of protein transfer or of gene expression regulation, mRNA 
expression of a number of genes with pro- and anti-inflammatory function was analyzed in monocytes by qPCR 
after 24 h of stimulation with MP. Upregulation of CD90 gene expression as a result of particles stimulation was 
observed in MP and MPγ treated monocytes (p < 0.05) (Fig. 5d). Moreover, expression of the anti-inflammatory 
factors IDO and PD-L1 was increased in monocytes treated with MPγ, but not MP (p < 0.05) (Fig. 5d). 
There was a trend for increased expression of IL-6 after MP and MPγ treatment, but this was not significant. 
Significant changes in gene expression were also not observed for the pro-inflammatory cytokines TNF-α and 
anti-inflammatory cytokine IL-10.
Membrane particles induce selective apoptosis of pro-inflammatory CD14+CD16+ mono-
cytes. Monocyte incubated for 24 h with MP and MPγ (1:10,000, 1:40,000, and 1:80,000 ratios) were analyzed 
by flow cytometry for apoptosis by Annexin V staining. MP and MPγ did not significantly induce apoptosis in 
classical monocytes (CD14+CD16−) (Fig. 6a). However, pro-inflammatory monocytes (CD14+CD16+) showed 
an increase (p < 0.05) in apoptosis after incubation with MPγ at a ratio of 1:40,000, and after incubation of MP 
and MPγ at ratios of 1:80,000 (Fig. 6b). This indicated that MP specifically induce apoptosis of pro-inflammatory 
monocytes.
Monocytes but not lymphocytes are able to take up Membrane Particles. Since the previous 
results showed that MP had immunomodulatory properties on monocytes but not on lymphocytes, we analyzed 
the interaction of MP with both types of immune cells. For that purpose, MP labeled with PKH membrane dye 
Figure 2. Characterization of Membrane Particles generated from unstimulated and IFN-γ stimulated AT-
MSC (MP and MPγ, respectively). (a) Nanoparticle tracking analysis (NTA) profiles of MP and MPγ. The NTA 
software generates a distribution graph on a particle-by-particle basis, a count (in terms of absolute number 
and concentration), and (b) size distribution of MP and MPγ. (c) The average number of particles generated 
per MSC. Data are presented as mean ± SD from 10 independent preparations of MP. There was no statistical 
difference with respect to concentration and size between MP and MPγ. The statistic test used was unpaired 
t-test. (d) Transmission electron microscopy analysis of MP. White arrows point to areas zoomed in on at the 
images on the right side. Most of the MP showed a round shape and a size below 200 nm.
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were added to PBMC (ratio 1:40,000) and incubated during 1 h and 24 h at 37 °C. As a control the cells were incu-
bated at 4 °C, at which temperature no active uptake of MP is expected. A representative flow cytometry analysis 
is showed in Fig. 7a and b.
1 h after the addition of MP, a small percentage of CD3-lymphocytes (1.3 ± 0.2%) were positive for PKH-MP 
(Fig. 7c) while 20 ± 5.3% of CD14-monocytes was able to uptake MP (p < 0.05) (Fig. 7d). The difference between 
the MP uptake by monocytes and lymphocytes was higher after 24 h (lymphocytes: 5.2 ± 1.4%, monocytes: 
93 ± 4.3%; p < 0.05). The 4 °C control for uptake was always below 3% for monocytes and lymphocytes in all the 
time points. This result indicated that MP uptake was mediated in an energy-dependent process.
Figure 3. Enzymatic activity of Membrane Particles. (a) ATPase activity was measured at four different 
concentrations of MP (1 × 1012, 1 × 1011, 1 × 1010 and 1 × 109 particles/ml). MP and MPγ were able to catalyze 
the breakdown of ATP and the detection of free phosphate was dependent on the concentration of MP. (b) The 
nucleotidase activity of the MSC marker CD73 was measured for three concentrations of MP (1 × 1012, 1 × 1011 
and 1 × 1010 particles/ml). MP and MPγ were able to produce free phosphates after adding AMP substrate in 
a dose-dependent fashion. CD73 enzyme (2 and 1 ng) was used to calculate the concentration of CD73 in the 
MP. There was no statistical difference in enzyme activity between MP and MPγ. (c) Esterase activity of three 
concentrations of MP (1 × 109, 1 × 108 and 1 × 107 particles/ml) was measured by the conversion of CFDA-SE 
to CFSE by flow cytometry. Fluorescent events were observed in MP labeled with CFSE (CFSE-MP), and the 
number of CFSE-MP detected was dependent on the concentration of MP. There was no statistical difference 
between MP and MPγ in esterase activity. Controls (PBS + CFSE and non-labeled MP) were negative. Data are 
presented as mean ± SD. Enzyme activities were detected in MP generated from 5 different MSC donors.
Figure 4. Effect of Membrane Particles on lymphocyte proliferation. CFSE loaded PBMC stimulated with 
anti-CD3/antiCD28 antibody were cultured with different ratios of MP for 4 days (1:5,000, 1:10,000, 1:40,000 
and 1:80,000). CFSE dilution in CD4+ and CD8+ T cells was measured. (a and b) Addition of MP or MPγ did 
not affect the proliferation of CD4+ and CD8+ T cells. (n = 8; mean ± SD). Two-way ANOVA was used for 
statistical analysis.
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To examine whether MP could be internalized by monocytes, confocal immunofluorescence microscopy was 
performed with isolated CD14+ cells from PBMC. The membrane of the monocytes was labeled with PKH-67 
and cultured with PKH-MP (1:40,000). Time-lapse recordings showed that MP bound to the plasma membrane 
of the monocytes but they were not internalized. To look in detail at the localization of MP on the monocytes, 
z-stack images were analyzed by confocal microscopy (Fig. 8). These images confirmed that MP remained local-
ized to the cell surface of the monocytes.
Discussion
The immunomodulatory capacity of MSC is often attributed to the secretion of soluble factors11. We recently 
demonstrated that inactivated MSC without the capacity to secrete factors can modulate immune responses in 
vitro and in vivo9. Inactivated MSC showed similar bio-distribution as living MSC as both are trapped in the 
lungs following intravenous administration. Here, we went one step further and generated nanoparticles from 
the membranes of adipose tissue MSC with diverse immunomodulatory properties by induction of regulatory 
proteins on the plasma membrane after treating the MSC with IFN-γ.
To generate MP, supernatants of MSC cultures were discarded and the cells were washed several times with 
PBS. Hereby the inclusion of soluble proteins in the MP preparations is avoided, which is a major challenge in the 
field of natural extracellular vesicles (EV) and causing misinterpretation of results31. The isolation methods for 
obtaining EV allow the co-precipitation of proteins, and RNA associated to lipoproteins secreted by the cells32. 
These contaminations mask the functional properties of EV and hamper their therapeutic application. With our 
novel protocol, we avoid the inclusion of artefacts from soluble molecules, and make MP a good alternative to EV.
Nanosight technology and electron microscopy were used for the characterization of MP. Most of the MP 
showed a size below 200 nm, and a round shape. Both characteristics make the MP an attractive therapeutic tool. 
Firstly, because their small size MP can easily maneuver through the capillary network of the lungs and reach sites 
of action beyond the lungs. Secondly, their morphology (closed circular structures) would allow loading of MP 
Figure 5. Effect of MP on CD14+ cells. Monocytes were cultured with different ratios of MP for 24 h (1:10,000, 
1:40,000 and 1:80,000) to determine the effect of MP on monocyte immunophenotype. (a) Expression of CD16 
on monocytes cultured in the presence of MP or MPγ (n = 6; mean ± SD). (b and c) Monocyte cell surface levels 
of CD90 and PD-L1 in the presence of MP or MPγ (n = 7; mean ± SD). (d) mRNA expression of monocytes 
after culture with MP. After 24 h of culture with MP or MPγ, monocytes were separated from MP and assessed 
by real-time RT-PCR for CD90, IDO, PD-L1, IL-6, TNF-α and IL-10 expression (n = 6; mean ± SD). Multiple 
comparison test (two-way ANOVA) was used for statistical analysis, *p < 0.05, **p < 0.01 and ***p < 0.001 vs 
control; #p < 0.05 and ##p < 0.01 vs MP group.
www.nature.com/scientificreports/
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with compounds of interest and use MP as a delivery vehicle for future applications. Sun et al. provided evidence 
that anti-inflammatory drugs can be loaded into EV from myeloid cells and thereby enhance the delivery of the 
drug to activated monocytes in a LPS-induced septic shock model33. The use of MP from MSC as a natural deliv-
ery vehicle would have the advantage that the vehicle per se show immunomodulatory properties, which gives the 
carrier additional value. It is also important to consider that the production and manipulation of MP is easier and 
cheaper than the methodology used for the collection of EV, as it is possible to generate about 1.5 × 105 particles/
cell.
In addition to their morphological characteristics, MP were shown to possess enzyme activity. It has been 
reported that extracellular vesicles from MSC have a cargo rich in enzymatically active glycolytic enzymes, 
ATPases, and ATP-generating enzymes, such as adenylate kinase and nucleoside-diphosphate kinase34. Enzymatic 
activity has been demonstrated to be important for modulating the conditions in the vesicle nano-environment 
by consuming or generating metabolic energy. Katsuda et al. demonstrated the unique potential of extracellu-
lar vesicles from adipose tissue derived MSC for treatment of Alzheimer´s disease. These authors found that 
these extracellular vesicles carry Neprilysin, a metalloprotease, which ameliorates the disease’s symptoms35. We 
showed that MP possess nucleotidase and esterase activity, which are major enzymes regulating immunity and 
inflammation21,22.
Lymphocyte proliferation is the most commonly used assay to demonstrate the immunomodulatory capacity 
of MSC and it has been used as a standard assay to compare the immunosuppressive effect of MSC from different 
tissue sources. Comparative studies have sometimes however produced conflicting results. Puissant et al. have 
reported similar inhibition of T cell proliferation by bone marrow and adipose tissue MSC36, whereas Ribeiro 
et al. found that adipose tissue MSC to have stronger suppressive effects than bone marrow and umbilical cord 
MSC8. In pilot experiments, we generated MP from bone marrow derived MSC. These MP demonstrated similar 
properties as MP from adipose tissue MSC.
The mechanisms through which MSC suppress lymphocyte proliferation are largely dependent on soluble 
mediators. In our study, we found no effect of MP on lymphocyte proliferation. This can be explained by the 
fact that MP cannot secrete soluble factors, but also because lymphocytes were shown to be unable to bind or 
uptake MP. However, MP induced modulation of monocyte cell surface markers expression and changed their 
immune function. Furthermore, MP and MPγ induced the selective apoptosis of proinflammatory CD14+CD16+ 
monocytes.
CD16+ monocytes are major producers of inflammatory cytokines such as TNF-α and IL-1237,38, and high 
numbers of CD16+ monocytes are associated with acute and chronic inflammatory conditions39. Our results 
therefore suggest that MP act as immunomodulators that eliminate pro-inflammatory monocytes. Importantly, 
Figure 6. Effect of MP on apoptosis of monocyte subsets measured by Annexin V staining. Monocytes were 
cultured overnight with 3 ratios of MP or MPγ (1:10,000, 1:40,000 and 1:80,000). (a) Percentage of Annexin 
V positive CD14+CD16− classical monocytes, and (b) percentage of Annexin V positive CD14+CD16+ pro-
inflammatory monocytes. Data represent mean ± SD of 5 experiments using MP from 3 different donors. Two-
way ANOVA was used for statistical analysis. P values (*p < 0.05) refer to the control without MP.
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we also found that the immunomodulation induced by MP and MPγ is different. MPγ but not MP increased 
PD-L1 in the membrane of the monocytes and the mRNA expression of the anti-inflammatory factor IDO. Thus, 
the modification of the membrane protein composition of MSC by treatment of the cells with various stimuli pro-
vides us the opportunity to generate MP adapted for treatment of a specific immunological disorder. For example, 
MPγ with their enhanced capacity to induce PD-L1 and IDO by monocytes may be suitable for treatment of 
more severe immune responses involving inflammatory monocytes, while MP derived from MSC pre-treated 
with factors that induce proteins with regenerative function may be useful for inducing regenerative processes 
after resolving inflammation. As there is a lot of knowledge about modulation of MSC properties by cytokine 
treatment, there are tools in hand to control the make-up of MP. Thus, the potential therapeutic applications of 
MP are far reaching.
We demonstrated that the interaction of MP with monocytes is by binding and fusion with the plasma mem-
brane of the monocytes. This is an active and specific mechanism for monocytes because at low temperatures 
MP were unable to fuse with the monocyte membranes. It is furthermore specific because MP do not bind to 
lymphocytes. The confocal microscopy images showed that there is no internalization of MP into monocytes, 
indicating phagocytosis plays no role in the uptake of MP. The mechanism of binding and fusion of MP with 
monocyte membranes supports the idea that MP can be a natural delivery vehicle for monocyte-targeting drugs.
In conclusion, MP represent a therapeutic strategy that combines the potential of MSC therapy with reduced 
risks associated with the use of living cells and improved ability to reach sites beyond the lungs. Our data demon-
strates that MP target monocytes, via which they may have a broad immunomodulatory effect (Fig. 9). These data 
suggest that MP can serve as a novel cell-free therapeutic for treating immunological disorders. Additional stud-
ies, both in vitro and in vivo, are needed to improve our understanding the mechanisms of action of this potential 
immunosuppressive tool.
Materials and Methods
Ethics statement and human tissue samples. The MSC were provided by Internal Medicine 
Department, Transplantation laboratory of the Erasmus MC (The Netherlands). The cells were isolated from 
subcutaneous adipose tissue from healthy donors that became available during the kidney donation procedure. 
Figure 7. Uptake of MP by monocytes. MSC were labeled with PKH-26 before generation of MP (PKH-MP). 
PKH-MP were added to PBMC (ratio 1:40,000) and incubated for 1 h and 24 h at 37 °C. As a control the 
experiment was incubated at 4 °C. (a and b) Representative flow cytometry analysis of PKH-MP uptake by 
lymphocytes (CD3) and monocytes (CD14) at time points 1 h and 24 h at 4 °C and at 37 °C. (c) Percentage 
of CD3+ T cells positive for PKH-MP, and (d) Percentage of CD14+ monocytes positive for PKH-MP. Data 
are presented as mean ± SD from 6 experiments. Two-way ANOVA was used for statistical analysis. P values 
(*p < 0.05) refer to the 4 °C control at the 1 h time point.
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The tissues were not procured from prisoners, and were collected after obtaining written informed consent for 
all patients, as approved by the Medical Ethical Committee of the Erasmus University Medical Centre Rotterdam 
(protocol no. MEC-2006-190). All experiments were performed in accordance with the approved guidelines.
Isolation and culture of MSC from adipose tissue. Subcutaneous adipose tissue from five healthy 
human kidney donors became available during the donation procedure. The adipose tissue was collected in min-
imum essential medium-α (MEM-α) (Sigma-Aldrich, St. Louis, MO) supplemented with 100 IU/ml penicillin, 
100 mg/ml streptomycin (P/S) (Lonza, Verviers, Belgium), and 2 mM L-glutamine (Lonza).
The tissue was mechanically disrupted and enzymatically digested with 0.5 mg/ml collagenase type IV in 
RPMI for 30 min at 37 °C under continuous shaking. Thereafter, the cells were resuspended in MEM-α with 
15% fetal bovine serum (FBS; Lonza), 2 mM L-glutamine and 1% P/S, filtered through a 100 µm cell strainer, and 
transferred to a 175 cm2 culture flasks (Greiner Bio-one, Essen, Germany).
Cultures were kept at 37 °C, 5% CO2, and 95% humidity, at 90% confluence; adherent cells were removed from 
culture flasks by incubation in 0.05% trypsin-EDTA (Life Technologies, Bleiswijk, The Netherlands) at 37 °C.
Two MSC culture conditions were used for the experiments: unstimulated MSC, and pretreated with IFN-γ 
(50 ng/ml, Sigma-Aldrich). After incubation for 3 days, MSC were collected to generate cell membrane particles. 
MSC were used for experiments between passages 2 and 6.
Immunophenotypic characterization of AT-MSC. Unstimulated and IFNγ-stimulated AT-MSC 
were trypsinized and washed with FACS Flow (BD Biosciences, San Jose, CA). Cell suspensions were incubated 
with mouse-antihuman monoclonal antibodies against CD13-PE-Cy7; HLA-DR-PERCP; HLA-ABC-APC; 
CD31-FITC; CD73-PE; PD-L1-PE (all BD Biosciences); CD90-APC and CD105-FITC (R&D Systems, Abingdon, 
UK) at room temperature in the absence of light for 30 min. After two washes with FACS Flow, flow cytometric 
analysis was performed using FACSCANTO-II with FACSDIVA Software (BD Biosciences).
Generation of cell Membrane Particles. Unstimulated and IFN-γ stimulated AT-MSC were trypsinized 
and washed twice with PBS. Then, the MSC were incubated in milliQ water at 4 °C until the cells exploded and 
liberated the nuclei (about 20 min). This step of the protocol was checked by microscopy. Then, the plasma mem-
brane of cells was fractionated by passing them through a 29 G needle several times.
Cell extracts were cleared of unbroken cells and nuclei by centrifugation at 2,000 × g for 20 min. The obtained 
supernatant was transferred to an Amicon Ultra-15 100 kDa device and concentrated by centrifugation at 4,000 x 
Figure 8. Confocal microscopy analysis of MP uptake by monocytes at 24 h. Z-stack images were collected at 
1.2 μm intervals ranging from 0 to 17.6 μm. Staining for monocyte membrane (green), MP (red), and nucleus 
(blue) shows that MP are localized on the membrane of the monocytes (white arrows) and are not internalized. 
Scale bars: 5 μm.
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g at 4 °C. The concentrated pellet consisted of crude plasma membrane and was diluted in 1 ml of 0.2 µm filtered 
PBS, cell culture medium or water. All procedures were performed on ice.
Nanoparticle tracking analysis (NTA). Analysis of absolute size distribution and concentration of MP 
was performed using NanoSight NS300 (NanoSight Ltd.). With NTA, particles are automatically tracked and 
sized based on Brownian motion and the diffusion coefficient. The analysis settings were optimized using as 
control filtered PBS and bovine serum albumin (BSA, Sigma-Aldrich) solution and kept constant between sam-
ples. The NTA measurement conditions were: detect threshold 3 (determined with the BSA solution), three 
Figure 9. Schematic overview of the interaction of MP with monocytes. MP generated from MSC bind to 
monocyte plasma membranes. As an effect of the MP-monocyte interaction, MP modulate monocyte function 
by affecting gene expression and inducing apoptosis of pro-inflammatory monocytes.
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measurements per sample (30 s/measurement), temperature 23.61 ± 0.8 °C; viscosity 0.92 ± 0.02 cP, frames per 
second 25. Each video was analyzed to give the mean, mode, median and estimated concentration for each parti-
cle size. The samples were diluted to obtain the right number of particles (1 × 108 particles/ml) in accordance with 
the manufacturer’s recommendations.
Transmission electron microscopy examination of MP. After fixation with paraformaldehyde (2%), 
all the samples were adsorbed for 20 min to glow-discharged carbon coated grids by floating the grids on 10 μL 
drops on parafilm. Grids with adhered MP were washed with water, stained with 2% uranyl acetate in water 
and examined in the electron microscope Tecnai T12 Spirit equipped with an Eagle CCD camera 4kx4k (FEI 
Company, Eindhoven, The Netherlands).
ATPase assay. ATPase activity from MP and MPγ was measured using an ATPase assay kit according to the 
manufacturer’s instructions (Sigma-Aldrich). A phosphate standard was used for creating a standard curve. MP 
(1 × 1012, 1 × 1011, 1 × 1010 and 1 × 109 particles/ml) were incubated with 4 mM ATP for 30 min at room temper-
ature in assay buffer with malachite green reagent. The formation of the colorimetric product that formed in the 
presence of free phosphates was measured with a spectrophotometer at 620 nm.
As a control for possible phosphate contamination, the four MP concentrations were incubated in assay buffer 
without ATP. The signal from these samples was subtracted from the samples incubated with ATP.
CD73 activity assay. A modified protocol of CD73 inhibitor screening assay kit (BPS Bioscience) was used 
to determine whether MP were able to degrade AMP into adenosine plus phosphate. MP and MPγ (1 × 1012, 
1 × 1011 and 1 × 1010 particles/ml) were incubated with AMP (500 μM) during 25 min at 37 °C. Then, colorimetric 
detection reagent was added to measure the free phosphate from the CD73 reaction. Samples without AMP were 
measured as a control for free phosphate contamination. CD73 enzyme (2 and 1 ng) was used to calculate the 
concentration of CD73 in the MP, and MPγ.
Esterase activity by CFSE. CFDA-SE, which is non-fluorescent, enters the cytoplasm of cells where intra-
cellular esterases remove the acetate groups and convert the molecule to a fluorescent ester (CFSE). This con-
version was used to detect whether MP have esterase activity. After MP generation, 1 × 1010, 1 × 109, 1 × 108 and 
1 × 107 particles/ml were labeled with 50 μM of CFDA-SE and incubated at 37 °C for 30 min. Dilution of the MP 
was performed to obtain a proper stoichiometry of the CFSE staining. PBS + CFDA-SE and non-stained MP were 
used as controls.
CFSE fluorescence was measured by flow cytometry (FACS Canto II, BD Biosciences). Due to the small size 
of the MP, reliable FSC and SSC measurements could not be obtained. Instead, MP were identified by setting a 
fluorescence threshold triggering on the CFSE fluorescence so that events above the threshold could be identified 
as CFSE-loaded MP.
CD3/CD28 T cell proliferation assay. To evaluate the immunomodulatory capacity of MP, PBMC were 
labeled with 1 μM of CFSE and plated in round bottom 96-well culture plates at a density of 5 × 104 cells/well. T 
cell proliferation was stimulated by adding human anti-CD3/anti-CD28 antibodies (1 µl/ml each) with a linker 
antibody Ig (2 µl/ml) (BD Biosciences). PBMC were incubated with different ratios of MP, or MPγ (1:5,000, 
1:10,000, 1:40,000, 1:80,000) for 4 days. On the fourth day, non-adherent PBMC were removed from the plate, 
washed with FACS Flow and incubated with monoclonal antibodies against CD4-PerCP and CD8-PE-Cy7 (anti-
bodies were purchased from BD Biosciences) at room temperature for 30 min. When a CFSE-labeled cell divides, 
its progeny are endowed with half the number of CFSE-tagged molecules and thus each cell division can be 
assessed by measuring the corresponding decrease in cell fluorescence by flow cytometry.
Interaction of MP with monocytes. CD14+ cells were purified from PBMC using auto-MACS Pro by 
positive-selection. Monocyte purity was measured by flow cytometry after staining with mouse-antihuman mon-
oclonal antibodies against CD14-PerCP (BD Biosciences) and CD3-PacBlue (BD Biosciences). Isolated CD14+ 
monocytes (2 × 105 cells/200 µl) were cultured in RPMI 1640 medium (Life Technologies), supplemented with 
10% FBS and 1% P/S. Monocytes were cultured with MP, or MPγ at different ratios (1:10,000, 1:40,000, 1:80,000) 
in polypropylene tubes. After 24 h of incubation, monocytes were collected for PCR analysis or flow cytometry 
after staining with CD14-PacBlue, CD3-PerCP, CD16-FITC, PD-L1-PE and CD90-APC (all BD Biosciences).
Quantitative RT-PCR analysis. Monocytes were harvested, washed with PBS-diethylpyrocarbonate 
(DEPC; Sigma-Aldrich) and stored at −80 °C. Total RNA was isolated and 500 ng used for complementary 
DNA (cDNA) synthesis. Gene expression was determined by Quantitative Real-Time PCR (qPCR) using the 
TaqMan Universal PCR Master Mix (Life Technologies), and the assay-on-demand primer/probes for CD90 
(Hs00264235_s1), PDL-1 (Hs00204257.m1), interleukin-6 (IL-6; Hs00174131.m1), IL-10 (Hs00174086.m1), 
tumor necrosis factor-α (TNF-α; Hs99999043.m1) (Thermo Fisher), and indoleamine 2,3-dioxygenase (IDO; 
Hs00158627.m1). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA served as housekeeping gene 
for normalization (Hs99999905.m1; Thermo Fisher).
Apoptosis of monocyte subsets. Monocytes were cultured with MP, or MPγ at different ratios (1:10,000, 
1:40,000 and 1:80,000) in polypropylene tubes overnight. Then, cells were incubated with monoclonal antibodies 
against CD14-Pacific Blue and CD16-FITC (antibodies were purchased from BD Biosciences) at room tempera-
ture for 30 min. After washing step, cells were stained with fluorochrome-conjugated Annexin-V for 15 min at RT 
to assess the apoptotic cells. All data were measured on a FACSCanto II flow cytometer (BD) and analyzed using 
FACSDiva software.
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MP uptake assays. To obtain fluorescent MP, MSC were labeled with the red fluorescent PKH-26 dye 
(PKH-MP), which intercalates into lipid bilayers, according to the manufacturer’s instructions (Sigma-Aldrich).
Human PBMC from healthy donors were isolated by density gradient centrifugation (Ficoll Isopaque, Sigma 
Aldrich) and cultured with PKH-MP (ratio 1:40,000). The incubation conditions were 37 °C, 5% CO2, and 95% 
humidity. As a control for the uptake process, PBMC were incubated with PKH-MP at 4 °C. PKH-MP uptake by 
lymphocytes and monocytes was analyzed by flow cytometry (FACS Canto II, Becton Dickinson) at 1 h, and 24 h.
Confocal microscopy analysis of PKH-MP uptake by monocytes was carried out by isolating CD14+ cells from 
PBMC using auto-MACS Pro by positive-selection (Miltenyi Biotec, Leiden, The Netherlands). Then, monocytes 
were labelled with PKH-67 (Life Technologies) and cultured with PKH-MP (ratio 1:4 × 104) for 24 h. The nuclei 
of the monocytes were stained with DAPI. Images of monocytes were performed on a Leica TCS SP5 confocal 
microscope (Leica Microsystems B.V., Science Park Eindhoven, Netherlands) equipped with Leica Application 
Suite – Advanced Fluorescence (LAS AF) software, DPSS 561 nm lasers, using a 60 X (1.4 NA oil) objective. 
Images were processed using ImageJ 1.48 (National Institutes of Health, Washington, USA).
Statistical Analysis. Data were analyzed for statistical significance either by Student’s t-test or one-way 
ANOVA analysis using GraphPad Prism 5 software. P < 0.05 was considered significant.
Availability of data and materials. All data generated or analyzed during this study are included in this 
published article. The rest of datasets generated and/or analyzed during the current study are not publicly availa-
ble due but are available from the corresponding author on reasonable request.
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